Sana Biotechnology Q3 2024 net loss $59.9M; advancing three clinical programs; cash runway into 2026

Sana Biotechnology, Inc.

2024-Q3 EPS reported -$0.95

Net loss of $59.9M ($0.25/sh) for Q3 2024 vs net income of $1.0M in Q3 2023.
Cash and equivalents $199.0M as of Sep 30, 2024; expected cash runway into 2026.
Appointed Dhaval Patel as Chief Scientific Officer; expanding focus on type 1 diabetes and B-cell autoimmune diseases.
Enrolling patients in three studies: UP421 (type 1 diabetes), GLEAM (SC291 autoimmune), VIVID (SC262 oncology); data expected in 2024/2025.
Non-GAAP operating cash burn $153.1M for first nine months 2024; strategic repositioning may increase 2024 burn above prior guidance of <$200M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.